AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE
Information current as at: 1 September 2026
Submission Details
- Brand name:
-
- MSUD Anamix Infant®
- MSUD Anamix Junior®
- MSUD Lophlex LQ 20®
- MSUD Maxamum®
- Form and strength:
-
- Oral powder 400 g (MSUD Anamix infant)
- Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior)
- Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20)
- Oral powder 500 g (MSUD Maxamum)
- Submission sponsor:
- NUTRICIA AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Short-chain enoyl-CoA hydratase (ECHS1) deficiency
- Listing requested:
- To request listing of MSUD Anamix Infant, MSUD Anamix Junior, MSUD Lophlex LQ 20 and MSUD Maxamum for the dietary management of infants and children with ECHS1 deficiency (the same dietary management approach used in Maple Syrup Urine Disease (MSUD)).
- Funding program:
- PBS General Schedule
- Request authority level:
- Restricted Benefit
- PBAC Submission type:
- Change to existing listing (Committee Secretariat)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2026
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC recommended extending the General Schedule Restricted Benefit listings for MSUD Anamix Infant, MSUD Anamix Junior, MSUD Lophlex LQ 20 and MSUD Maxamum to include patients with short-chain enoyl Co-A hydratase 1 (ECHS1) deficiency and 3-hydroxyisobutyryl Co-A hydrolase (HIBCH) deficiency.
The PBAC noted and supported advice from the Nutritional Products Working Party that these products are clinically appropriate for the dietary management of ECHS1 and HIBCH deficiencies. The PBAC also welcomed input from the Mito Foundation, which supported the proposed extension and highlighted the benefits of improved access to clinically recommended dietary therapy for patients with these rare metabolic disorders.
The PBAC considered the estimated financial impact of the proposed listing extension was appropriate.